There are many unanswered questions around the novel coronavirus Covid-19. Not everyone responds in the same way to the virus.
Why do some people get hospitalized and others are asymptomatic? We are hoping to help uncover which type of people are more immune than others and thus ideal donors, while in turn identifying at-risk persons who normally would have thought they would be fine to better protect them.
We need to utilize our existing resources, our Covid-19 survivors and their plasmac, to help save lives now (direct transfusion) as well as route towards research (tests/vaccine) purposes.
What are the qualifications to donate convalescent plasma?
Both a confirmed negative and a antibody test. We need both to ensure that there is no longer viral shedding and that one has been exposed and has ample antibodies present. Initially guidance required a former prior FDA-lab Positive test, but given the lack of testing and number of asymptomatic cases, this has since been modified.
Where can I get tested for antibodies and donate plasma?
We are working with partners to combine rapid antibody testing and donations. We are also mapping out existing testing centers to help get routed to testing and subsequent donation through our standardized intake form.
For overall Convalescent Plasma Guide & Resources:
Mayo Clinic and FDA Program: https://www.uscovidplasma.org/
AABB Iniative: https://covidplasma.org
The following are resources on blood testing centers in the meantime:
America’s Blood Centers: www.americasblood.org
American Red Cross: www.redcrossblood.org
Armed Services Blood Program: www.militaryblood.dod.mil
Blood Centers of America: www.bca.coop
What happens to my blood or plasma after I donate? What impact can an indivual have right now?
A single plasma donation from an average, healthy adult can treat approximately 2 people (200ml). With opt-in consent, we are hoping to also allocate a small portion to qualified researchers through the Blood Bank Network. The primary focus is to save lives now, secondary but also important is research and development of new tests, vaccines and treatments.
How should we prioritize testing for donations?
It’s not so simple – but we have put a lot of thought and research into this.
1) Front-line healthcare and other essential workers who are high-risk for contracting or having already contracted COVID-19.
2) Previously COVID-19 confirmed positive cases in overall healthy individuals that fit the standard criteria for blood and plasma donations that have subsequently been testing negative for current infection and positive for antibodies.
How are you using my data?
Without your opt-in consent, data is simply being captured at the macro level for internal development purposes and proper regulatory reporting guidelines. If you are looking for further information or support on donating plasma we will be in contact.
If you opt-in for research and or clinical trials, your anonymized data could be utilized with your blood samples alongside other important data such as symtom and outcome tracking to identify immune/risk profiles and help establish new treatments and vaccines.
If you opt-in for outreach for clinical trials and further research, you may be contacted (without revealing your identity to the third party until you respond affirmatively) about potential paid or unpaid research and clinical trials opportunities.
How can you help get this plan and protocol implemented in your hospital, city, etc?
Please request and reach out to us and we will help consult to bring in your healthcare system and other city leaders to activate campaigns. We will soon have a more efficient and developed supply chain for convalsecent plasma but currently most treatment is dependent on local recovered covid-19 patient plasma.
Hospitals should sign up for the Mayo Clinic Site Registration for US Expanded Access Program for Convalescent Plasma for the Treatment of Patients with COVID-19. Even if a hospital is not currently enrolled in the expanded access program – individual physicians and patients can apply for EIND, emergency Investigational New Drug approval. If you or your loved one is ineligble for existing alternative IND therapies (pre-existing conditions or specific circumstances) – please consult with your doctor to discuss as we believe many lives can be saved through convalescent transfusion.
This is not direct medical advice – and there are potential risks associated with plasma transfusion.
Risks commonly associated with FFP include: (1) transfusion related acute lung injury; (2) transfusion associated circulatory overload, and (3) allergic/anaphylactic reactions. Other less common risks include (1) transmission of infections, (2) febrile non-hemolytic transfusion reactions, (3) RBC allo-immunization, and (4) hemolytic transfusion reactions. – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356109/